Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Bullboard Posts
Comment by longterm56on May 19, 2019 8:44pm
85 Views
Post# 29760059

RE:RE:Grinspoon data published soon?

RE:RE:Grinspoon data published soon? Why do we expect the full report ti five the stock if the top line data .... which are the highlights ... didn't? I think there is a 70% chance that the publication of the report will be another big yawn for the public. -LT
PinnacleX wrote:
SPCEO1 wrote: I have heard from a pretty good source that we may have the full Grinspoon data published in about two weeks. Which may be why the company indicated at the annual meeting that we will get the NASH strategy in now about 2 1/2 weeks. It also sounds like it will contain something new and meaningful, which is no surprise since you do not get to jump the line in JAMA or NEJM unless you have something special in your article. Now, this is second or third hand info so take that into account. But it makes sense from a timing perspective. So, if it is an accurate report, we get the publication around 5/30, then the NASH strategy the following week. After that we should have an investor day scheduled, followed by the NASDAQ listing, which will hopefully be accompanied by an offering which will hype TH's NASH potential. Now, don't expect the stock to jump until the data is out because the market is not paying attention to this and has rather bizarrely ignored the preliminary NASH info so far. But if it is true that the NASH opportunity for TH is significant, as many signs suggest, it will not be ignored forever.


You have insider knowledge.  WOW. 



Bullboard Posts